

1 The diversity of clinical *Mycobacterium*
2 *abscessus* isolates in morphology,
3 glycopeptidolipids and infection rates in a
4 macrophage model.

5

6

7

8 Virginia Pichler^{1,3}, Lara Dalkilic¹, Ghazaleh Shoaib¹, Tirosh Shapira¹, Leah Rankine-Wilson¹, Yves-
9 Marie Boudehen³, Joseph Chao¹, Danielle Sexton¹, Miguel Prieto², Bradley Quon², Elitza
10 Tocheva¹, Laurent Kremer³, William Hsiao⁵, Yossef Av-Gay^{1,2}

11

12

13 ¹ Department of Microbiology and Immunology, Life Sciences Institute, University of British
14 Columbia, Vancouver, Canada

15 ² Department of Medicine, University of British Columbia, Vancouver, Canada

16 ³ INSERM, IRIM, 34293 Montpellier, France.

17 ⁴ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada

18

19 # corresponding author: yossi@mail.ubc.ca

20

21

22

23 **Abstract**

24

25 *Mycobacterium abscessus* (Mab) colonies adopt smooth (S) or rough (R) morphotypes, which
26 are linked to the presence or absence of glycopeptidolipids (GPL), respectively. Though clinically
27 relevant, the association between GPL levels, morphotype and pathogenesis are poorly
28 understood. To investigate the degree of correlation between Mab morphology, GPL levels,
29 and infectivity, we generated isolates from Mab-positive sputum samples from cystic fibrosis
30 patients. Isolated strains were categorised based on their morphology, GPL profile, and
31 replication rate in macrophages. Our findings revealed that around 50% of isolates displayed
32 mixed morphologies and GPL analysis confirmed a consistent relationship between GPL content
33 and morphotype was only found in smooth isolates. Across morphotype groups, no differences
34 were observed *in vitro*, yet using a high-content THP-1 cell *ex vivo* infection model, clinical R
35 strains were observed to replicate at higher levels. Moreover, the proportion of infected
36 macrophages was notably higher among clinical R strains compared to their S counterparts at
37 72 hours post-infection. Clinical variants also infected at significantly higher rates compared to
38 laboratory strains, highlighting the limited translatability of lab strain infection data to clinical
39 contexts. Our study confirmed the general correlation between morphotype and GPL levels in
40 smooth strains yet unveiled more variability within morphotype groups than previously
41 recognised, particularly during intracellular infection. As the rough morphotype is of highest
42 clinical concern, these findings contribute to the expanding knowledge base surrounding Mab
43 infections, offering insights that can steer diagnostic methodologies, and treatment
44 approaches.

45

46 **Introduction**

47

48 Non-tuberculous mycobacteria are a class of saprophytic bacteria represented by over 180
49 species. Ubiquitously found in the environment (soil, water, vegetation), a subset is classified
50 as opportunistic pathogens for their ability to occupy human niches, primarily as pulmonary or
51 soft tissue infections and frequently affecting immunocompromised individuals [1-4]. The most
52 abundant pathogenic species belong to the *Mycobacterium avium* complex (MAC;
53 *Mycobacterium avium*, *Mycobacterium intracellulare*) and *Mycobacterium abscessus* complex
54 (MABSC: *Mycobacterium abscessus abscessus* (Mab), *Mycobacterium abscessus massiliense*
55 (Mma), *Mycobacterium abscessus bolletii* (Mbo)), the latter which remains an ongoing
56 treatment challenge due to its intrinsic resistance to growing incidence of broader antibiotic
57 resistance [5-6].

58 Mycobacteria follow a similar pathogenesis strategy, primarily infecting hosts via aerosol
59 inhalation where they interact with and are engulfed by the innate immune cells, namely
60 macrophages, where they survive and replicate in phagocytic vesicles [2, 7-8]. This strategy has
61 been well-documented in Mab infections and is associated with the transition of the bacteria
62 from the smooth (S) to rough (R) morphotype [8]. The difference in intracellular behaviour
63 between the two types has been linked to the presence of glycopeptidolipids (GPL) [2]. Cell
64 surface GPL decorate the S morphotype and mask underlying TLR-2 agonists, such a
65 phosphatidyl-myo-inositol dimannoside (PIM2) [9] and lipoproteins [10] and allow for greater
66 initial colonisation in loner phagosomes. Conversely, R morphotypes are associated with a
67 strong immunological response, persistent infections and presence in social phagosomes.

68

69 The colony morphology of the S morphotype has been described as a uniformly round shape,
70 shiny and luxuriant (Figure 1, left), whereas the R morphotype is often irregular in shape, matte,
71 wrinkled, and textured (Figure 1, right). The characteristics of these opposite morphologies has,
72 indeed, been widely described in the literature, however, to our knowledge no deliberate study
73 has been performed to determine a strict set of criteria for each progressive morphotype
74 between the canonical extremes, represented by the S and R laboratory strains ATCC19977/
75 CIP104536 S/R, denoted as Cip^S and Cip^R throughout. However, rarely do clinical manifestations
76 perfectly mirror their lab counterparts. This is of importance as morphological transition is a
77 marker of infection progression and establishing these criteria will help reduce inter-observer
78 variability when reporting diagnostic results [11]. Furthermore, following consistent
79 morphological plasticity tracking metrics between clinics and research facilities will help build
80 a more robust pool of data to reveal the full extent of the relationship between morphotype
81 and infection persistence and severity. Herein, we describe the isolation, molecular analysis,
82 and intracellular growth of 46 clinical isolates from cystic fibrosis patients, represented by an
83 approximate equal distribution of the S and R morphotypes.

84

85 **Materials and Methods**

86

87 ***Clinical Isolates***

88 This study used a total of 46 laboratory-confirmed mycobacterial isolates that were obtained
89 from 19 CF patients in St Pauls Hospital (Vancouver, Canada). Isolates were confirmed through
90 MALDI-TOF MS and 16s rRNA target sequencing and obtained from the B.C. Centre for Disease
91 Control (BCCDC).

92

93 ***Strain separation***

94 BCCDC glycerol stocks were streaked onto Luria Bertani (LB) agar plates and incubated at 37 °C
95 for 4-6 days. Isolates were visually inspected for morphotype composition at high resolution
96 with the Zeiss Axio Zoom V16 microscope according to the categorical descriptors in Table 1.
97 Plates containing heterogenous populations were re-streaked until pure, stable morphotypes
98 were achieved. Single colonies were inoculated in 7H9 Broth (Difco™ Middlebrook)
99 supplemented with 10% (v/v) OADC (0.05% oleic acid, 5% bovine albumin fraction, 2%
100 dextrose, 0.004% catalase, and 0.8% sodium chloride solution) and 0.05% (v/v) Tween 80,
101 termed 7H9OADCT throughout. Glycerol stocks of each step were stored at -80 °C.

102

103

104 ***Lipid Extraction***

105 Fresh bacterial lawns on LB agar were harvested and pelleted in glass vials by centrifugation at
106 2,000g for 5 min. Polar lipids (GPL) were extracted using the chloroform-methanol method, as
107 described previously [12]. Final extracts were solubilized in 300 µL of chloroform/methanol (2:1
108 v/v). Lipids were visualised with thin layer chromatography (TLC) by adding 20 µL of sample on
109 a silica gel 60 F254 sheet (Merck) and placed in a chloroform/methanol/water (90:10:1, v/v/v)

110 solution for migration. An orcinol-sulfuric acid solution (0.2% and 20%, respectively) was
111 sprayed onto the sheet and the plates were lipid profiles revealed using heat. GPL were
112 detected with reference to the control strains (Cip^S, CIP104536T (S) and Cip^R, CIP104536T (R)).
113 Replicates were performed for strains where morphotype categorisation did not align with the
114 TLC results.

115

116 Ex-vivo THP-1 macrophage infection model

117

118 *Construction of an integrative vector expressing a fluorescent marker*

119 Derivative versions of the integrative plasmid pMV306 [13-14] were constructed to allow strong
120 expression of either mScarlet (pMV306-mScarlet, Figure S1) or mWasabi (pMV306-mWasabi)
121 fluorescent proteins with a kanamycin resistant cassette for selection. This plasmid contains
122 pMV306 integrase *attP* as a one-step integration construct. Briefly, the mScarlet or mWasabi
123 coding sequences, placed under the control of the constitutive P left* promoter, were PCR-
124 amplified by Q5® High-Fidelity DNA Polymerase (New England Biolabs) using plasmid L5
125 *attB::Pleft*mScarlet/mWasabi* (Addgene plasmids 169410 and 169409, respectively) as DNA
126 templates [15]. Primer pairs, dual forward primer P*:
127 ATCTTAAATCTAGATGGCCGCGGTACCAGATCTT, mScarlet reverse primer:
128 AGCTGGATCCATGGATTCACTTGTACAGCTCGTCCATGCC, mWasabi reverse primer:
129 AGCTGGATCCATGGATTACTTGTACAGCTCGTCCATGCC. The linear fragments were purified on
130 agarose gels (NucleoSpin Gel and PCR Clean-up, Macherey- Nagel). Following the
131 manufacturer's instructions, Pro Ligation-Free Cloning Kit (abm®) reactions were performed to
132 insert these linear fragments into the pMV306 previously digested with EcoRV and transformed
133 into *Escherichia coli* (*E. coli*) Stellar TM competent cells (Takara Bio), purified (NucleoSpin

134 Plasmid, Macherey-Nagel) and verified by DNA sequencing. Plasmids were then electroporated
135 into the *M. abscessus* strains [16-17] and recombinant clones harbouring the constructs
136 inserted at the attL5 insertion site in the glyV tRNA gene were selected for on 7H10 agar
137 supplemented with 0.5% glycerol, 10% OADC, and 50 µg/ml kanamycin (7H10OADCkan).

138

139

140 *Bacterial and THP-1 Cell Culturing*

141 Unless otherwise stated, all bacterial strains were transformed with pMV306-mScarlet and
142 routinely grown from stock at 37 °C in 7H9OADC with 50 µg/ml kanamycin, termed
143 7H9OADCkan. THP-1 human monocyte-derived macrophage-like cells (ATCC TIB-202) cells
144 were grown in incomplete RPMI1640 medium (10% FBS, 2% glutamine and 1% non-essential
145 amino acids) at 37 °C with 5% carbon dioxide (CO₂). Cell density was kept between 0.25 and 1
146 × 10⁶ cells/mL for a maximum of three months.

147

148

149 *Infection*

150 THP-1 cell suspension at 5 × 10⁵ cells/mL in incomplete RPMI1640 was seeded into a 96-well
151 plate at 50,000 cells/well and differentiated into a macrophage-like state over a period of 48
152 hrs with phorbol12-myristate13-acetate (PMA, 40 ng/mL) at 37 °C with 5% CO₂. Liquid bacterial
153 cultures were grown to mid-log phase in 100 µL per well in a round-bottomed 96-well plate
154 (VWR), centrifuged (5,000g, 10 min) and washed once with sterile Dulbecco's phosphate-
155 buffered saline (DPBS, Gibco). Cultures were de-clumped using a 25G blunt needle, transferred
156 to a flat-bottomed 96-well plate (VWR) and OD₆₀₀ was measured (OD₆₀₀ of 1 ≈ 1.13 × 10⁹
157 CFU/mL) using the Varioskan LUX™ microplate reader (Thermo Fisher Scientific). Inoculums of
158 a multiplicity of infection (MOI) of 2 bacteria per macrophage was prepared in incomplete RPMI

159 and opsonised with 10% non-decomplemented human serum for 30 min at 37 °C, shaking.
160 Differentiated macrophages were washed once with warm DPBS and inoculated with the
161 opsonized bacterial suspensions for three hrs (37 °C, 5% CO₂). Wells were washed twice with
162 DPBS and treated with amikacin (250 µg/mL) for one hr to remove any extracellular bacteria.
163 The amikacin was removed, and wells were washed a final time with DPBS and replaced with
164 100 µL incomplete RPMI containing 1 µg/mL Hoechst 33342. Plates were incubated for three
165 days at 5% CO₂ at 37 °C. Testing of each strain was performed in technical triplicates.

166

167 *High-content intracellular growth analysis*

168 Intracellular bacterial growth was monitored using the CellInsight™ CX5 High Content Platform
169 (Thermo Fisher Scientific) using methods previously described by our group [18-19]. Briefly,
170 macrophages were identified and counted through nuclei staining and a mask was created to
171 represent the entire cell, or region of interest (ROI/circle). Red channel fluorescence (569/593
172 nm) was used to detect bacteria “spots” inside the cellular ROI. These spots were quantified
173 using a variety of measurements including intensity and area using the Thermo Fisher
174 ScientificTM HCS StudioTM Cell Analysis Software. These fluorescent measurements closely
175 correspond with colony-forming units (CFU), as previously validated [20]. Data were plotted
176 using GraphPad Prism version 10 (GraphPad Software, Boston, Massachusetts USA,
177 www.graphpad.com). Measurements were captured at multiple time points to monitor
178 replicate rate and bacterial burden. Super-resolution fluorescence light microscopy of the 62S
179 and 62R isolates expressing mScarlet was used to determine morphotype differences after 72
180 hrs of infection: macrophages were differentiated onto coverslips and infection was carried out
181 as described above, after which, cells were fixed with 4% paraformaldehyde and imaged using
182 Zeiss LSM 900 confocal microscope equipped with an Airyscan 2 detector and a Colibri 5 light

183 source. Images were collected with a Plan-Apochromat 100x/1.46 oil objective lens and
184 processed using Zen Blue 2.4 software.

185

186 **Results**

187

188 *Subspecies distribution in CF isolates is predominantly Mab.*

189 19 patients provided 43 unique sputum samples, which were characterised by the BCCDC into
190 46 clinical isolates, and further categorized in this study, resulting in 75 individually
191 characterised clinical morphotype strains. Subspecies representation was dominated by Mab
192 in categories such as prevalence within patients (n=14, 73.68%), and total clinical isolates
193 (n=38, 82.61%), (Table 2). Mma was the next most prevalent, with the subspecies isolated in 5
194 of the 19 patients (26.32%). Mbo was isolated from the single sputum sample provided by
195 patient 16. Smooth and rough morphotypes were evenly distributed amongst patients, isolates
196 and strains. 18 patients returned both smooth and rough morphotypes in their sputum
197 samples, and of the 46 BCCDC isolates collected, 27 (58.7%) were further separated into
198 defined both smooth and rough morphotype strains. All BCCDC isolates were correctly
199 identified to the subspecies level.

200

201 *Colony morphology variation among Mab clinical isolates*

202 Colonies were isolated and subcultured several passages to ensure pure morphotypes were
203 reproducible and stable. Strain colonies were inspected using high resolution zoom microscopy
204 and evaluated for morphotype composition. Colonies most often presented as having uniform
205 margins and smooth texture (smooth, "S", Figure 1, left) or irregular margins with rough texture
206 throughout (rough, "R", Figure 1, right) and were classified accordingly.

207

208 *Visual subcategorization of smooth-like colonies lacks reproducibility.*

209 In addition to the canonical morphotypes, several strains appeared as ‘intermediates’, along a
210 spectrum between smooth and rough (Figure 2A). A sub-morphotype classification system was
211 initially used to categorise these intermediates, by way of “S-”, “S-” and “R-”, where S- (Figure
212 2A, *ii-iv*), is more similar to the reference S morphotype (Figure 2A, *i*), than S--, which displays
213 further edge ruffling and is more matte in appearance (Figure 2A, *v-vi*). This categorization
214 strategy became unwieldy, in that there was no definitive characteristic that would separate
215 any one subcategory from their neighbour, and the variability of shape and texture extended
216 beyond these three discrete groupings. In addition, the intermediate colony morphology strains
217 were often not stably reproducible after repeated subculturing. This phenomenon was
218 observed with both intermediate transitioning to smooth, and vice versa over time. We did not
219 observe, nor subsequently explicitly test for morphotype transition to true rough, and later
220 recategorized S- and S-- into the recognised S morphotype class.

221

222 *Some *Mab massiliense* isolates exhibit density-dependent intermediate morphology.*

223 The putative ‘R-’ category was defined as individual colonies that consistently carried rough-
224 like features, yet when plated densely, would harbour a central, smooth-like phenotype with
225 rough edges (Figures 2B/C). This phenotype was observed in three patients’ unique sputum
226 samples and always belonged to Mma subspecies. 12 (16%) of the 75 strains belonged to Mma.
227 Patient 10 provided two individual samples, one year apart, both only containing Mma (Table
228 2). The first sample yielded a strict R morphotype Mma (70R), while the second sample
229 contained all three morphotypes (S=80S, R=80R, R-=80R-). To further characterise these
230 morphotypes, we next experimentally assessed lipid composition in each strain to determine
231 the presence of GPL.

232

233 *GPL lipid profiles correlate with colony morphology in Mab more than Mma*

234

235 GPL presence was qualitatively assessed using thin layer chromatography (TLC) of lipid extracts.

236 This assay is a simple way to score strains as GPL-positive or-negative by the presence or

237 absence of banding, respectively (Figure 3A). GPL presence and strain morphotype were

238 correctly matched in 100% Mbo and S typed strains and ~97% of Mabs isolates (unmatched

239 n=1, J.R). We recorded five patients who provided samples that contained Mma, which were

240 categorised by BCCDC into seven (15.2%) isolates, that we further classified into 12 distinct

241 strains. As previously stated, three of these samples were identified as putative R- morphotype

242 (67R-, 80R- & 82R-), all of which displayed clear banding in the GLP region of the TLC assay,

243 indicating presence of glycopeptolipids. (Figure 3B-C). Retrospectively, all 12 strains would

244 belong to the smooth morphotype group when considering GPL production.

245

246 The strains were subcultured into both solid and liquid media to ensure purity and lipids re-

247 extracted a total of three times, each instance generating consistent results. Furthermore, the

248 GPL profile to morphotype inconsistency was observed in three Mma strains that were grouped

249 as strict R (70R, 80R & 82R). Mma strains 67, 80 and 82 also possessed strict S morphotypes,

250 showing that Mma has more than one morphology associated with the presence of GPL. This

251 leads us to question whether colony morphology should be supported as a method of

252 morphotyping in Mma strains, and further highlights the inconsistency with this method across

253 all MABSC species. We report the GPL production of Mma strains is not readily determined by

254 visual inspection of colony morphology.

255

256

257 *High-content evaluation reveals intracellular replication is highest among clinical R strains.*

258 A THP-1 macrophage infection model was used to better approximate the behaviour of the
259 separated strains in the context of host. A total of 69 strains, including reference strains, were
260 successfully electrotransformed with the pMV306-mScarlet integrative plasmid containing the
261 red fluorescent protein, which was used to identify intracellular bacteria burden over time.
262 Relative fluorescence from the transformed bacteria were tracked over three days to assess
263 intracellular replication rate. All fluorescence values were normalised to the first time point at
264 4 hrs to account for any variations in the MOI. Intracellular bacterial burden was evaluated
265 using several parameters, including the relative replication rate of each strain to its respective
266 lab strain, degree of variance between replicates, and the comparison of each morphotype by
267 collapsing data from all strains into S, R, or R- categories.

268

269 *Growth characteristics of the R- subtype is more closely related to S morphotype than R.*

270 To evaluate each clinical strain relative to its respective lab strain (Cip^R or Cip^S), a multiple
271 comparisons test was performed with a one-way ANOVA on relative fluorescence captured at
272 multiple time points (Figure 4A) and presented as individual, isogenic pairwise and grouped
273 (Figure 4B, C and D, respectively). Cip^S replicated at a rate approximately six-fold greater than
274 Cip^R and was found to be statistically significant ($p<0.001$). Interestingly, clinical strains
275 replicated faster than their cognate lab strain, a characteristic not often reported in clinical
276 strain research. When grouped as isogenic pairs, faster growth was also observed in most R
277 strains compared S strains in the macrophage model (Figures 4C). Indeed, when looking at
278 isogenic strain pairs, nearly all R strains replicated about twice as fast as their S counterparts.
279 Of these, isolates 62, 77, M, A, K and 30 were found to be significantly different. Isolates 77, M
280 and K are sequential collections from Patient 1 and possess both S and R morphotypes. These

281 strains had similar replication rates which were significantly greater ($p<0.01$) than that of the
282 isolate (FR) collected two months prior, indicating a degree of Mab population stability over the
283 subsequent 18 months of infection (Table 2). Isolates 30 and 62 were the bookends of serial
284 samples provided by Patient 5 for this study and also returned significance between the S and
285 R replication rates, though no significant differences between the other isolates of Patient 5
286 were found. The replication rate of *in vitro* growth was also measured by OD₆₀₀ and revealed
287 negligible differences between S and R morphotypes, after 72 hours (Figure 4E).

288

289 To investigate morphotypes as a group, all fluorescence data were collapsed into the discrete
290 S, R and R- clusters to evaluate for broader trends, not otherwise discernible from individual
291 pairs (Figure 4D). All R strains collectively showed a significant two-fold growth to the S strains
292 at 24, 48 and 72 hrs showing intracellular growth is indeed higher in R than S. The putative R-
293 strain closely matched the replicative behaviour of the smooth strains and replicated at a
294 significantly slower rate compared to the bona-fide R group.

295 Considering the faster growth of clinical isolates seen in this study, we wanted to see if variance
296 was affected to a greater extent in clinical strains, and if so, which morphotypes contribute to
297 such variation. We performed a Levene's test to evaluate i) the degree of variance between
298 replicates within a single strain and ii) if any significant differences existed between strains (data
299 not shown). As expected, variance was greatest at 72 hours across all strains, all though no
300 significant differences were observed between strains ($p>0.05$).

301

302

303

304 *Reference strains Cip^S and Cip^R infect macrophages at different rates compared to their clinical
305 counterparts.*

306 The proportion of infected THP-1 macrophages was calculated as a percentage of macrophages
307 with intracellular Mab burden over the total macrophage population per condition (Figure 5A).
308 Cip^S infected a significantly greater proportion of cells compared to the clinical S strains. The
309 clinical R strains (n=22) infected a greater percentage of macrophages, both compared to the
310 lab strain (Cip^R) and the clinical S strains (n=31) at 72 hrs post-infection (p<0.05). The high
311 replication rate of Cip^S compared to the clinical S strains complements the higher proportion
312 of macrophages infected. Clinical R strains replicated faster and infected a greater proportion
313 of infected macrophages compared to the Cip^R, whereas inversely, clinical S strains replicated
314 slower and a lesser proportion of infected macrophages compared to Cip^S. This highlights a
315 divergence in pathogenesis of the clinical strains from their associate lab strains. No significant
316 loss in THP-1 survival was seen over the course of infection, either between morphotypes or
317 strains. Further microscopic analysis of the variants revealed that indeed a feature of the R
318 morphotype at later time points is the formation of extensive extracellular cording, exceeding
319 the size of macrophages and hampering phagocytosis as a clearance strategy (Figure 5B/C/D).

320
321

322 **Discussion**
323

324 This study's aim to characterise smooth and rough morphotypes of *M. abscessus* clinical
325 infections was initiated with the separation of strains into the two discrete groups. Strict S
326 colonies are characterised by a uniformly round shape, smooth margin, an absence of interior
327 texture and a beige or brown colour, while strict R colonies are characterised by an irregular
328 shape, rough margins, interior texture and a gray colour (Table 1, Figure 1). After multiple

329 passages of each strain to attain sample purity, it became evident that these two morphotype
330 classes were insufficient to capture the full morphological spectrum.

331

332 *Colony morphology*

333 Subculturing methods aim to isolate a single, pure, stable sample with only one morphotype
334 present. We found some isolates readily conformed to a stable morphotype, but some were
335 highly variable over more than five passages. It is important to note that subcultures with
336 mixed populations never generated both strict S and R morphotypes on the same plate, but
337 rather contained several sub-morphotypes appearing as 'intermediates' between S and R.

338 Initially, these intermediates were classified as 'S+', S++' and 'R-' and fell serially between S and
339 R (i.e., S, S-, S--, R-, R). A subculture isolated from a strict S colony may yield S, S+ and S++ on

340 the same plate, while other strains would only yield more strict S colonies. While the
341 intermediates continued to appear in the subcultures, the inability to successfully isolate
342 consistent sub-morphotypes indicate morphological variations as transient features.

343 Conditions that may have affected colony morphology, such as density, culture age, and media
344 type likely contributed to the observed variability, however, a separate sub-study would need

345 to be performed to properly characterise the full range of factors involved, as has been done
346 on *Pseudomonas aeruginosa* [11]. Despite this limitation, all strains were separated and
347 classified broadly as S and R; all S sub-morphotypes (S+ and S++) fell under the umbrella of S

348 while all strains classified as R adopted the strict morphotype. The 'R-' sub-morphotype, while
349 appearing most like the R morphotype, presented with less texture and brown, rather than

350 gray, in colour (Figure 2C). Additionally, this sub-morphotype forms concentrated, smoothed
351 patches when plated as a lawn (Figure 2B), a feature absent in the strict R morphotype, which

352 is consistently sharply textured even when plated to lawn density. Notably, when reviewing the

353 associated clinical metadata, all strains that possessed the R- sub-morphotype belonged to a
354 congruent subspecies, Mma, and was observed in three of the total seven isolates. While these
355 findings have revealed a common feature of this subspecies' colony behaviour, the R- sub-
356 morphotype was 1) found in mixed populations, often among strict S and R colonies, and 2) not
357 ubiquitous across all seven Mma strains, and therefore cannot serve as a stable speciation proxy
358 for all Mma isolates with microscopy.

359

360 *High-content investigation into MABSC infection dynamics*

361 Clinical *M. abscessus* research has predominantly been performed *in vitro*, which does not
362 adequately reproduce the complexity of the host environment and immunological responses
363 to infection [21]. As the presence of GPL is an important factor in *M. abscessus* pathogenesis,
364 evaluating these bacteria as they interact with macrophages provides a better opportunity to
365 investigate the contributing role of GPL during infection. *For M. abscessus*, a knowledge gap
366 that exists regarding the heterogeneity of a bacterial population and their dynamics during
367 infection may be resolved using high-content analysis. When collapsed by morphotype, we
368 found no significant differences in *in vitro* growth data between groups (Figure 4E). A THP-1
369 macrophage infection model was then used to better approximate behaviour *ex vivo*. We found
370 inverse relationships between clinical and reference morphotyped strains in their ability to
371 infect a population of THP-1 cells over time (Figure 5A). We also noted clinical R strains grew
372 faster than Cip^R in our infection model, a trait that reversed in S morphotypes (Figure 4B).
373 Employing three technical replicates within each experiment was chosen to balance precision
374 and resource efficiency, given that the 54 strains broadly fell into two categories.

375

376 Traditional CFU/mL assays include a consistent amikacin treatment to control for extracellular
377 growth, thus ensuring that colony quantification post-lysis exclusively comes from the
378 intracellular environment, however, this ignores the process of bacterial escape from
379 macrophage lysis. Mab infection persistence is a combination of two strategies: 1) intracellular
380 survival and apoptosis suppression by the S morphotype, and 2) bacterial escape and
381 extracellular aggregate colonization ('cording') by the R morphotype (Figure 5B/C/D) [1, 8]. By
382 removing the amikacin treatment step over the course of the infection, a truer reflection of
383 infection burden could be seen due to free movement of the bacteria within and between
384 macrophages. Capturing the increase in percent of infected cells demonstrates a degree of
385 bacterial escape and new macrophage infection. Our results show that at 48 and 72 hrs post-
386 infection, the percent of infected macrophages increased in both morphotypes, clinical and lab
387 strains alike. One limitation must be addressed in that our pool of clinical R strains, including
388 most R- strains, was depleted due to difficulty with mScarlet transformation. Some strains
389 underwent several transformation attempts, with additional cell wall perforation methods to
390 enhance DNA uptake [17]. Transformation of mycobacterial species can be especially
391 challenging due to the complex composition of in the cell wall, which often hampers uptake of
392 foreign DNA. The abundance of lipids in the cell wall additionally renders the bacilli
393 hydrophobic, resulting in clumping when grown in media and necessitating the use of de-
394 clumping methods during the preparation of electrocompetent single cells. Rough morphotype
395 strains have been noted as the most challenging to transform and most often form clumps [1].
396 This was the case for these clinical strains, with ~88% (n=7) of those unsuccessful belonging to
397 the rough morphotype.
398

399 Nevertheless, the greatest increased observed of infected macrophages were observed in the
400 Cip^S, clinical R, clinical S and finally Cip^R, reaffirming that the clinical strains do not predictably
401 follow the behaviour of their associated lab strains. Identifying this divergence holds broad
402 implications for our understanding of Mab pathogenesis and persistence. Many studies [1, 7,
403 22-24] have delved into the importance of morphotype distinction, their unique intracellular
404 behaviours, and their strategies to successfully persist in the host environment, but our findings
405 highlight that the features observed in lab strains may be insufficient to fully appreciate the
406 complete diversity and variability found in clinical strains. Most infection studies to date have
407 been completed using reference strains (ATCC199977/CIP104536S/R) alone or fewer than ten
408 clinical isolates, limiting the translatability of the results to authentic clinical contexts [1, 24-
409 27]. This seems to be especially salient as not only do our results show the breadth of
410 behaviour across the strains during infection but show that clinical morphotypes broadly
411 behave inversely to their lab counterparts.

412
413 While the overall trend showed clinical R strains replicating at higher rates than the S strains,
414 large ranges were still observed within each morphotype, with some of the strains more closely
415 matching their associated lab strain. Isogenic strains also varied by fold-difference after 72
416 hours. 83% of R strains replicated faster than their S counterparts, with 75% of the faster
417 growing R strains replicating at 2-3-fold greater than their S strain pair. Of the pairs that saw S
418 strain outgrow R, we highlight the profiles of Patients 1 and 4, where earlier isolates (F and 54,
419 respectively) showed slower replication in the R versus S. However, this trait was reversed in
420 the isogenic pairs from the next patient collection (77 and 57, respectively). In both instances,
421 this was accompanied by the decline in lung function capacity (data not shown). R colony
422 density and shape variability has been noted by Park et al. (2015) [28] in the context of

423 progressive disease, however, the full phenotype spectrum has yet to be elucidated, as is
424 evident by our findings of varied intracellular replication rate and other data describing
425 mutational and transcriptional changes [27, 29-30]. Strains 25S and 50S displayed the greatest
426 amount of intracellular growth within their morphotype at 72 hrs p.i., however, these two
427 strains belong to the subspecies Mma and Mbo, respectively, which could account for notable
428 difference.

429
430 The higher proportion of infected cells seen in clinical R morphotype may be due to bacterial
431 escape and subsequent increased macrophage TLR receptor engagement to
432 immunostimulatory surface molecules, such as PIMs and lipoproteins, that are otherwise
433 masked by GPL in the S morphotype [31]. The stable cell survival between both morphotypes,
434 and increase in infected cells over time do not support the supposition of macrophage
435 apoptosis and bacterial release. The increase in infected macrophages without cell lysis may
436 attributed in part, to the stimulation of tunneling nanotubes (TNTs), membrane channels that
437 connect cells as a rescue function during stress for the transfer of essential cellular
438 components, such as mitochondria [32]. TNT-like structures have been shown to play a role in
439 dissemination of several intracellular pathogens and have been observed in other
440 mycobacteria, including *M. marinum* and *M. bovis* BCG [33-34].

441

442 **Conclusions**

443
444 This study aimed to further characterise the morphological variations and behaviours exhibited
445 within clinical *M. abscessus* infections. We revealed a relationship between clinical and
446 reference strain behaviour in both phenotypic morphotype and intracellular behaviour.

447 We highlight the complexity of working with clinical isolates, particularly with the heterogeneity
448 of intracellular replication observed even within each morphotype group. By evaluating strain
449 pairs in an intracellular model, we observed R strain enhanced growth rate compared with S,
450 which likely contributed in part to R strain variability. Together, these data encourage the
451 development of specific R and S strain methodologies when assessing host-pathogen
452 relationships.

453

454 Considering these findings, we suggested that the existing S-to-R framework should be
455 considered more as a reference point rather than an absolute standard. This framework can
456 serve as a foundation to drive deeper comprehension of infection progression, as well as the
457 development of virulence and resistance mechanisms. Embracing a more flexible approach to
458 morphotype classification could facilitate a more nuanced understanding of *M. abscessus*
459 infections and aid in the development of more effective therapeutic interventions.

460

461 **Conflicts of interest**

462 None declared.

463

464

465 **Funding**

466 Funding for this research was provided by the Friedman Award for Scholars in Health (UBC,
467 awarded to V. Pichler), Cystic Fibrosis Canada (AWD-021084, awarded to Y. Av-Gay), and the
468 French National Research Agency ANR grants 19-CE15-0012-01 (SUNLIVE, awarded to L.
469 Kremer).

470

471

472 **Acknowledgments**

473 The authors wish to thank M. Ko, F. Roquet-Baneres, W. Daher for technical assistance and
474 helpful discussions.

475

476 **References**

- 477 1. Roux AL, Viljoen A, Bah A, Simeone R, Bernut A, Laencina L, Deramaudt T, Rottman M, Gaillard JL, Majlessi L, Brosch R. The distinct fate of smooth and rough *Mycobacterium abscessus* variants inside macrophages. *Open biology*. 2016 Nov 1;6(11):160185.
- 478 2. Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of *Mycobacterium abscessus*. *Nature Reviews Microbiology*. 2020 Jul;18(7):392-407.
- 479 3. Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. *Mycobacterium abscessus* complex infections in humans. *Emerging infectious diseases*. 2015 Sep;21(9):1638.
- 480 4. Abdelaal HF, Chan ED, Young L, Baldwin SL, Coler RN. *Mycobacterium abscessus*: it's complex. *Microorganisms*. 2022 Jul 19;10(7):145.
- 481 5. Clary G, Sasindran SJ, Nesbitt N, Mason L, Cole S, Azad A, McCoy K, Schlesinger LS, Hall-Stoodley L. *Mycobacterium abscessus* smooth and rough morphotypes form antimicrobial-tolerant biofilm phenotypes but are killed by acetic acid. *Antimicrobial agents and chemotherapy*. 2018 Mar;62(3):10-128.
- 482 6. Phelps GA, Cheramie MN, Fernando DM, Selchow P, Meyer CJ, Waidyarachchi SL, Dharuman S, Liu J, Meuli M, Molin MD, Killam BY. Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in *Mycobacterium abscessus*. *Proceedings of the National Academy of Sciences*. 2024 Jan 9;121(2):e2314101120.
- 483 7. Bernut A, Herrmann JL, Kiss K, Dubremetz JF, Gaillard JL, Lutfalla G, Kremer L. *Mycobacterium abscessus* cording prevents phagocytosis and promotes abscess formation. *Proceedings of the National Academy of Sciences*. 2014 Mar 11;111(10):E943-52.
- 484 8. Gutiérrez AV, Viljoen A, Ghigo E, Herrmann JL, Kremer L. Glycopeptidolipids, a double-edged sword of the *Mycobacterium abscessus* complex. *Frontiers in microbiology*. 2018 Jun 5;9:1145.
- 485 9. Rhoades ER, Archambault AS, Greendyke R, Hsu FF, Streeter C, Byrd TF. *Mycobacterium abscessus* glycopeptidolipids mask underlying cell wall phosphatidyl-myo-inositol mannosides blocking induction of human macrophage TNF- α by preventing interaction with TLR2. *The Journal of Immunology*. 2009 Aug 1;183(3):1997-2007.
- 486 10. Roux AL, Ray A, Pawlik A, Medjahed H, Etienne G, Rottman M, Catherinot E, Coppée JY, Chaoui K, Monsarrat B, Toubert A. Overexpression of proinflammatory TLR-2-signalling

507 lipoproteins in hypervirulent mycobacterial variants. *Cellular microbiology*. 2011
508 May;13(5):692-704.

509 11. Sousa AM, Machado I, Nicolau A, Pereira MO. Improvements on colony morphology
510 identification towards bacterial profiling. *Journal of microbiological methods*. 2013 Dec
511 1;95(3):327-35.

512 12. Daher W, Leclercq LD, Johansen MD, Hamela C, Karam J, Trivelli X, Nigou J, Guerardel Y,
513 Kremer L. Glycopeptidolipid glycosylation controls surface properties and pathogenicity
514 in *Mycobacterium abscessus*. *Cell chemical biology*. 2022 May 19;29(5):910-24.

515 13. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young
516 JF, Lee MH, Hatfull GF, et al. New use of BCG for recombinant vaccines. *Nature*. 1991
517 Jun 6;351(6326):456-60. doi: 10.1038/351456a0.

518 14. Huff J, Czyz A, Landick R, Niederweis M. Taking phage integration to the next level as a
519 genetic tool for mycobacteria. *Gene*. 2010 Nov 15;468(1-2):8-19.

520 15. Kolbe K, Bell AC, Prosser GA, Assmann M, Yang HJ, Forbes HE, Gallucci S, Mayer-Barber
521 KD, Boshoff HI, Barry III CE. Development and Optimization of Chromosomally-
522 Integrated Fluorescent *Mycobacterium tuberculosis* Reporter Constructs.. *Front
523 Microbiol*. 2020 Dec 9;11:591866. doi: 10.3389/fmicb.2020.591866. eCollection 2020.
524 10.3389/fmicb.2020.591866 PubMed 33362741

525 16. Medjahed H, Singh AK. Genetic manipulation of *Mycobacterium abscessus*. *Current
526 Protocols in Microbiology*. 2010 Aug;18(1):10D-2.

527 17. Campo-Pérez V, del Mar Cendra M, Julián E, Torrents E. Easily applicable modifications
528 to electroporation conditions improve the transformation efficiency rates for rough
529 morphotypes of fast-growing mycobacteria. *New biotechnology*. 2021 Jul 25;63:10-8.

530 18. Rankine-Wilson L, Rens C, Sahile HA, Av-Gay Y. *Mycobacterium tuberculosis* Infection of
531 THP-1 Cells: A Model for High Content Analysis of Intracellular Growth and Drug
532 Susceptibility. *Methods in Molecular Biology* (Clifton, NJ). 2022 Jan 1;2427:73-82.

533 19. Richter A, Strauch A, Chao J, Ko M, Av-Gay Y. Screening of preselected libraries targeting
534 *Mycobacterium abscessus* for drug discovery. *Antimicrobial Agents and Chemotherapy*.
535 2018 Sep;62(9):10-128.

536 20. Richter A, Shapira T, Av-Gay Y. THP-1 and dictyostelium infection models for screening
537 and characterization of anti-mycobacterium abscessus hit compounds. *Antimicrobial
538 Agents and Chemotherapy*. 2019 Dec 20;64(1):10-128.

539 21. Victoria L, Gupta A, Gómez JL, Robledo J. *Mycobacterium abscessus* complex: a review
540 of recent developments in an emerging pathogen. *Frontiers in cellular and infection*
541 *microbiology*. 2021 Apr 26;11:659997.

542 22. Tsai SH, Lai HC, Hu ST. Subinhibitory doses of aminoglycoside antibiotics induce changes
543 in the phenotype of *Mycobacterium abscessus*. *Antimicrobial agents and*
544 *chemotherapy*. 2015 Oct;59(10):6161-9.

545 23. Byrd TF, Lyons CR. Preliminary characterization of a *Mycobacterium abscessus* mutant
546 in human and murine models of infection. *Infection and immunity*. 1999 Sep
547 1;67(9):4700-7.

548 24. Kam JY, Hortle E, Krogman E, Warner SE, Wright K, Luo K, Cheng T, Manuneedhi Cholan
549 P, Kikuchi K, Triccas JA, Britton WJ. Rough and smooth variants of *Mycobacterium*
550 *abscessus* are differentially controlled by host immunity during chronic infection of
551 adult zebrafish. *Nature Communications*. 2022 Feb 17;13(1):952.

552 25. Ordway D, Henao-Tamayo M, Smith E, Shanley C, Harton M, Troutd J, Bai X, Basaraba
553 RJ, Orme IM, Chan ED. Animal model of *Mycobacterium abscessus* lung infection.
554 *Journal of Leucocyte Biology*. 2008 Jun;83(6):1502-11.

555 26. Bernut A, Dupont C, Sahuquet A, Herrmann JL, Lutfalla G, Kremer L. Deciphering and
556 imaging pathogenesis and cording of *Mycobacterium abscessus* in zebrafish embryos.
557 *JoVE (Journal of Visualized Experiments)*. 2015 Sep 9(103):e53130.

558 27. Pawlik A, Garnier G, Orgeur M, Tong P, Lohan A, Le Chevalier F, Sapriel G, Roux AL,
559 Conlon K, Honoré N, Dillies MA. Identification and characterization of the genetic
560 changes responsible for the characteristic smooth-to-rough morphotype alterations of
561 clinically persistent *Mycobacterium abscessus*. *Molecular microbiology*. 2013
562 Nov;90(3):612-29.

563 28. Park IK, Hsu AP, Tettelin H, Shallom SJ, Drake SK, Ding L, Wu UI, Adamo N, Prevots DR,
564 Olivier KN, Holland SM. Clonal diversification and changes in lipid traits and colony
565 morphology in *Mycobacterium abscessus* clinical isolates. *Journal of clinical*
566 *microbiology*. 2015 Nov;53(11):3438-47.

567 29. Chhotaray C, Wang S, Tan Y, Ali A, Shehroz M, Fang C, Liu Y, Lu Z, Cai X, Hameed HA,
568 Islam MM. Comparative analysis of whole-genome and methylome profiles of a smooth
569 and a rough *Mycobacterium abscessus* clinical strain. *G3: Genes, Genomes, Genetics*.
570 2020 Jan 1;10(1):13-22.

571 30. Li B, Ye M, Zhao L, Guo Q, Chen J, Xu B, Zhan M, Zhang Y, Zhang Z, Chu H.
572 Glycopeptidolipid genotype correlates with the severity of *Mycobacterium abscessus*
573 lung disease. *The Journal of Infectious Diseases.* 2020 Mar
574 16;221(Supplement_2):S257-62.

575 31. Parmar S, Tocheva EI. The cell envelope of *Mycobacterium abscessus* and its role in
576 pathogenesis. *PLoS Pathogens.* 2023 May 18;19(5):e1011318.

577 32. Mittal R, Karhu E, Wang JS, Delgado S, Zukerman R, Mittal J, Jhaveri VM. Cell
578 communication by tunneling nanotubes: Implications in disease and therapeutic
579 applications. *Journal of cellular physiology.* 2019 Feb;234(2):1130-46.

580 33. Marzo L, Gousset K, Zurzolo C. Multifaceted roles of tunneling nanotubes in intercellular
581 communication. *Frontiers in physiology.* 2012 Apr 10;3:72.

582 34. Tiwari V, Koganti R, Russell G, Sharma A, Shukla D. Role of tunneling nanotubes in viral
583 infection, neurodegenerative disease, and cancer. *Frontiers in Immunology.* 2021 Jun
584 14;12:680891.

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603 **Figure legends**

604

605 **Figure 1.** Characteristic two morphotypes of *M. abscessus*. A. smooth (left) and rough (right).

606 The smooth (S) morphotype is shiny and luxuriant with a uniformly round shape; the rough (R)

607 morphotype is matte, wrinkled, and textured with an irregular in shape.

608

609 **Figure 2.** A. *M. abscessus* morphology variability. Several 'intermediates' colony subtypes (*ii-vii*)

610 appear among clinical strains and deviate from the strict smooth or rough morphotype,

611 represented by the first and last images in the series. B. The putative 'R-' phenotype appears

612 rough in individual colonies but adopts a smooth-like characteristic when plated densely (white

613 arrow). C. Putative 'R-' colony with rugged edges, smoother centre and brown colour.

614

615 **Figure 3.** Glycopeptidolipid profiles. A. Cell surface glycopeptidolipids (GPL) are shown in the

616 upper banding of the TLC, with DAT, TMM, and PIM lipids making up the lower bands. GPL

617 present in isolates F and M are smooth morphotypes and match the associated lab strain (*Cip^S*);

618 isolate G is a rough morphotype and matches its associated lab strain (*Cip^R*). GPL will be present

619 on TLC of mixed morphology isolates, as the rough morphotype is confirmed only by the

620 absence of GPL. Mixed isolates should first be subcultured into pure morphotypes before polar

621 lipid extraction and visualised on a TLC. B. TLC of GPL composition in several clinical isolates,

622 already separated by morphotype. 70R and 80R/R- were morphologically categorised as rough

623 strains yet present with GPL banding. Isolates 70 and 80 are serial collections from the same

624 patient and belong to the subspecies *Mma*, which may indicate morphological features unique

625 to the subspecies that differ from *Mab*. C. Repeat extraction and TLC of isolates 70 and 80 to

626 confirm GPL presence.

627

628 **Figure 4.** Clinical strain growth rates. A. Relative fluorescence intensity of intracellular *M.*

629 *abscessus* clinical strains at 24, 48, and 72 hrs, as normalised to the 4-hr starting time point. All

630 strains were prepared to the same starting inoculum concentration and left to infect THP-1

631 macrophages for 3 hrs in triplicate, followed by a 1-hr 250 µg/mL amikacin treatment to clear

632 any remaining extracellular bacteria. Lower fluorescence intensity is represented in pale green

633 and high intensity in dark blue. Broadly, S strains (left of plot) replicate as a slower rate than the

634 R strains (right of plot), with the greater divergence appearing at 48 and 72 hrs. Reference

635 strains Cip^S and Cip^R adopt the inverse replication rate to their clinical counterparts. Overall,
636 there is greater replication rate variability among the R strains. Isolate 82R-, which was
637 classified as an 'intermediate' morphotype clusters more closely with the S strains. Other
638 notable outliers, including 25S and 50S belong to the subspecies Mbo and Mma, respectively.
639 B. Intracellular bacterial growth of all isolates at 72 hrs post-infection, grouped by variant. C.
640 Intracellular bacterial growth of isogenic pairs at 72 hrs post-infection. A one-way ANOVA
641 showed statistical significance between the lab strains, Cip^S and Cip^R ($p = 0.0016$), and
642 additionally between the isogenic pairs of 62 ($p = 0.009$), 77 ($p = 0.038$) and M ($p = 0.0052$). D.
643 All strains collapsed into morphotype group over 72 hrs. There were no significance differences
644 in rate between groups (S, n=37; R, n=35; R-, n=3). E. Clinical isolate intracellular bacterial
645 replication measured through fluorescence intensity, collapsed by morphotype (S, n=31; R
646 n=22; R-, n=1). R strains replicate at a rate approximately 2-fold higher than that of the S strains
647 and differ significantly at 24, 48 and 72 hrs p.i. The 'R-' intermediate strain (n =1) significantly
648 differed from the R strains, but not the S, indicating it clusters with the intracellular replication
649 behaviour of the S morphotype.

650

651 **Figure 5.** Infection burden. A. Percent of THP-1 macrophage infection by morphotype, clinical
652 and lab strain. The proportion of infected THP-1 macrophages was significantly greater among
653 the R clinical strains compared to their S counterparts at 72 hrs post-infection. Clinical
654 morphotype groups also infected a greater percentage of THP-1 macrophages compared to
655 their associated lab strains. B. High content fluorescent microscopy (CellInsight™ CX5 High
656 Content platform, Thermo Fisher Scientific) image of isolate 62R at 72 hrs post-infection.
657 Macrophage nuclei are stained blue and Mab is expressing mScarlet, with notable cording
658 forming extracellularly. C/D. Super-resolution fluorescence light microscopy of 62R (D) and 62S
659 (E) isolates, 72 hrs post-infection. The R morphotype is found on the surface of macrophages
660 (outlined with white dashed line) with distinct 'cording' appearance indicative of cell aggregates
661 too large for clearance by phagocytosis.

662

663 **Figure S1.** Construct map of the pMV306-mScarlet plasmid.

	Cip ^S	Cip ^R
Appearance	Shiny	Matte, textured
Colour	Brown	Gray
Margin	Uniform	Irregular
Glycopeptidolipid	Present	Absent
Infection stage	Colonising	Persistent
Antibiotic resistance	Low	High

Table 1. Canonical features of smooth (Cip^S) and rough (Cip^R) morphotypes.

Patient (n=19)	Isolate (n=46)	Isolation Date (YYYY-MM-DD)	Species	Morphotypes		
				S (n=37)	R (n=35)	'R-' (n=3)
1	10	2013-03-07	Mab	•		
	F	2018-06-08	Mab	•	•	
	77	2018-08-15	Mab	•	•	
	M	2019-01-17	Mab	•	•	
	K	2020-02-03	Mab	•	•	
	J	2021-05-05	Mab	•	•	
	G	2021-05-05	Mab		•	
2	8	2013-06-24	Mab	•	•	
	26	2014-03-09	Mab		•	
	45	2015-07-12	Mab	•	•	
	49	2016-03-18	Mab	•	•	
	D	2016-10-05	Mab		•	
	I	2017-06-09	Mab		•	
3	79	2018-07-09	Mab	•		
	76	2018-08-13	Mab	•		
	C	2018-08-13	Mma	•		
	B	2018-12-01	Mab	•		
4	54	2016-06-28	Mab	•	•	
	57	2016-10-21	Mab	•	•	

	L	2019-05-09	Mab	•	•
	A	2019-09-19	Mab	•	•
5	30	2014-12-01	Mab	•	•
	43	2015-05-10	Mab		•
	52	2016-06-20	Mab	•	•
	62	2017-01-19	Mab	•	•
6	E	2018-10-29	Mab	•	•
	81	2018-10-29	Mab	•	•
7	50	2016-03-31	Mma	•	
	82	2018-05-12	Mma	•	•
8	29	2014-11-20	Mab	•	
	42	2015-09-21	Mab	•	•
9	27	2014-02-10	Mab	•	
	72	2018-10-01	Mab	•	•
10	70	2017-10-15	Mma		•
	80	2018-09-27	Mma	•	•
11	22	2014-04-30	Mab	•	
	N	2019-01-23	Mab		•
12	6	2013-04-18	Mab	•	•
13	7	2013-05-28	Mab		•
	15	2013-11-29	Mab	•	•
14	16	2013-05-12	Mma	•	
15	23	2014-01-06	Mab		•
16	25	2014-03-09	Mbo	•	•
17	67	2017-09-07	Mma	•	
18	75	2018-08-09	Mab	•	•
19	H	2019-05-22	Mab	•	•

Table 2. Patient sample isolation dates, species and morphotype categorisation.






Figure 1

A



B



C




Figure 2






Figure 3


A



B



D



E




Figure 4







Figure 5




Figure S1